These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31774820)

  • 1. How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: The case of Luangwa District, Zambia.
    Silumbwe A; Halwindi H; Zulu JM
    PLoS Negl Trop Dis; 2019 Nov; 13(11):e0007861. PubMed ID: 31774820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach.
    Njomo DW; Kibe LW; Kimani BW; Okoyo C; Omondi WP; Sultani HM
    PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008499. PubMed ID: 32936792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya.
    Kusi C; Steinmann P; Merten S
    Infect Dis Poverty; 2020 Mar; 9(1):22. PubMed ID: 32114985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana.
    Manyeh AK; Ibisomi L; Ramaswamy R; Baiden F; Chirwa T
    PLoS Negl Trop Dis; 2020 Aug; 14(8):e0007009. PubMed ID: 32804967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana.
    Biritwum NK; Garshong B; Alomatu B; de Souza DK; Gyapong M; Kyelem D
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005619. PubMed ID: 28493966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of MDA registers for Lymphatic Filariasis: Findings, and potential uses in addressing the endgame elimination challenges.
    de Souza DK; Gass K; Otchere J; Htet YM; Asiedu O; Marfo B; Biritwum NK; Boakye DA; Ahorlu CS
    PLoS Negl Trop Dis; 2020 May; 14(5):e0008306. PubMed ID: 32407319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards elimination of lymphatic filariasis in southeastern Madagascar: Successes and challenges for interrupting transmission.
    Garchitorena A; Raza-Fanomezanjanahary EM; Mioramalala SA; Chesnais CB; Ratsimbasoa CA; Ramarosata H; Bonds MH; Rabenantoandro H
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006780. PubMed ID: 30222758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia.
    Krentel A; Wellings K
    Parasit Vectors; 2018 Mar; 11(1):179. PubMed ID: 29530082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment.
    Ahorlu CSK; Koka E; Adu-Amankwah S; Otchere J; de Souza DK
    BMC Public Health; 2018 Feb; 18(1):238. PubMed ID: 29433461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for lymphatic filariasis and mass drug administration non-participation in Mandalay Region, Myanmar.
    Dickson BFR; Graves PM; Aye NN; Nwe TW; Wai T; Win SS; Shwe M; Douglass J; Wood P; Wangdi K; McBride WJ
    Parasit Vectors; 2021 Jan; 14(1):72. PubMed ID: 33482891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: Perceptions and experiences of community drug distributors of coastal Kenya.
    Njomo DW; Kimani BW; Kibe LW; Okoyo C; Omondi WP; Sultani HM
    PLoS Negl Trop Dis; 2020 Dec; 14(12):e0009012. PubMed ID: 33370300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: A case study.
    Wodnik BK; Louis DH; Joseph M; Wilkers LT; Landskroener SD; Desir L; Lemoine JF; Lavery JV
    PLoS Negl Trop Dis; 2020 May; 14(5):e0008318. PubMed ID: 32469860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strengthening of mass drug administration implementation is required to eliminate lymphatic filariasis from India: an evaluation study.
    Lahariya C; Mishra A
    J Vector Borne Dis; 2008 Dec; 45(4):313-20. PubMed ID: 19248659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.
    Krentel A; Damayanti R; Titaley CR; Suharno N; Bradley M; Lynam T
    PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005027. PubMed ID: 27812107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa.
    Silumbwe A; Zulu JM; Halwindi H; Jacobs C; Zgambo J; Dambe R; Chola M; Chongwe G; Michelo C
    BMC Public Health; 2017 May; 17(1):484. PubMed ID: 28532397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing knowledge about lymphatic filariasis and the implementation of mass drug administration amongst drug deliverers in three districts/cities of Indonesia.
    Titaley CR; Damayanti R; Soeharno N; Mu'asyaroh A; Bradley M; Lynam T; Krentel A
    Parasit Vectors; 2018 May; 11(1):315. PubMed ID: 29801511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Keeping communities at the centre of efforts to eliminate lymphatic filariasis: learning from the past to reach a future free of lymphatic filariasis.
    Krentel A; Gyapong M; McFarland DA; Ogundahunsi O; Titaley CR; Addiss DG
    Int Health; 2020 Dec; 13(Supplement_1):S55-S59. PubMed ID: 33349882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health beliefs and health seeking behavior towards lymphatic filariasis morbidity management and disability prevention services in Luangwa District, Zambia: Community and provider perspectives.
    Maritim P; Silumbwe A; Zulu JM; Sichone G; Michelo C
    PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009075. PubMed ID: 33617551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya.
    Njomo DW; Amuyunzu-Nyamongo M; Magambo JK; Njenga SM
    PLoS One; 2012; 7(11):e48395. PubMed ID: 23185256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential factors influencing lymphatic filariasis transmission in "hotspot" and "control" areas in Ghana: the importance of vectors.
    Pi-Bansa S; Osei JHN; Frempong KK; Elhassan E; Akuoko OK; Agyemang D; Ahorlu C; Appawu MA; Koudou BG; Wilson MD; de Souza DK; Dadzie SK; Utzinger J; Boakye DA
    Infect Dis Poverty; 2019 Feb; 8(1):9. PubMed ID: 30717788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.